Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by tdon1229on Sep 15, 2017 9:24am
119 Views
Post# 26700133

RE:RE:RE:Strong technical analysis

RE:RE:RE:Strong technical analysisRayzzer,

Thank you for the link...I see where the first 3 were scheduled to be followed monthly for the first 3 months, then again at 6 months which appears to be a bit more screening than the trial design, but certainly makes for more effective following of their progress.

As for the "phenomenal" quote, I caution that this was/is the good doctor's personal comment, as he clearly states...earlier it was noted that there is a 30% bar set by the FDA which any trial needs to eclipse, so 2 of 9 would be somewhat less than phenomenal to the FDA, and 3 of 9 would be just clearing the FDA bar.

macman and/or LaserStock29,
I now see the source, but I've learned the hard way not to read too much into what is not clearly written...will the results for the first 3 at 6 mos.be published, or will they be held in abeyance for later viewing (e.g., when the results for the 6 are formally reviewed)...Ph1b is under way, so these results are not gating items for proceeding with the trial, but may be for the company's interest and for completeness only.
Bullboard Posts